Clinical

Dataset Information

0

Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients


ABSTRACT: This is a multicentre, open-label, Phase I/II study of enadenotucirev in patients with either solid tumour of epithelial origin not responding to standard therapy or for whom no standard treatment exists (Phase I dose escalation stage Single cycle), mCRC not responding to standard therapy (Phase I dose escalation Repeat cycle cohort expansion stage ), mCRC not responding to standard therapy or advanced or metastatic bladder cancer not candidate for chemotherapy (Phase Ib) or mCRC in stable disease or partial response after 3-4 months of first line standard of care chemotherapy (Phase II).

DISEASE(S): Metastatic Colorectal Cancer,Solid Tumours Of Epithelial Origin,Colorectal Neoplasms,Metastatic Bladder Cancer

PROVIDER: 2158183 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Shared Molecules

Only show the datasets with similarity scores above: 0.5
     

Similar Datasets

| 2530712 | ecrin-mdr-crc
| 2204711 | ecrin-mdr-crc
2024-01-01 | E-MTAB-12686 | biostudies-arrayexpress
2016-05-05 | E-MTAB-3548 | biostudies-arrayexpress
2012-01-01 | E-GEOD-32048 | biostudies-arrayexpress
2014-02-06 | GSE54740 | GEO
2024-01-25 | GSE248663 | GEO
2024-10-04 | GSE278391 | GEO
2012-01-01 | GSE32048 | GEO